Priority Date: 27.11.09 (US 20090264748P)

ELIGLUSTAT (GENZ 112638) AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE FOR USE IN A METHOD OF TREATING FABRY'S OR GAUCHER'S DISEASE, THE METHOD COMPRISING ADJUSTING THE INDIVIDUAL THERAPEUTICAL DOSE TO THE P-450 METABOLISM OF THE PATIENT

  • Application ID: EP16175117
  • Status: EXAMINATION IN PROGRESS

Applicant

Technology company logo small
Technology Company

Attorney

no operation time available
Headquarter in London and 5 offices
active in Legal Services and Matchmaking and Trading

Specialization

This EP application has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY). Mathys & Squire LLP is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 229 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 27.11.2009 - Priority Date (US 20090264748P)
  • 22.02.2017 - Publication A1 (EP3133070)